OncoMatch/Clinical Trials/NCT07092566

R.E.C.K vs Exparel in Robotic Nephrectomy

Is NCT07092566 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for renal carcinoma.

Treatment: Ropivacaine HCL · Exparel · Epinephrine · Clonidine HCL · Ketorolac — The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.